使用68Ga-FAPI PET/CT检测乳腺髓系肉瘤并评估化疗早期反应
Use of 68Ga-FAPI PET/CT for Detecting Myeloid Sarcoma of the Breast and Assessing Early Response to Chemotherapy.
PubMed 文献 · Clin Nucl Med · 2022-01-12
本病例报告描述一名18岁女性左乳腺活检证实的髓系肉瘤患者,比较18F-FDG与68Ga-FAPI PET/CT表现,68Ga-FAPI PET/CT在左乳腺肿块中显示远优于18F-FDG PET/CT的肿瘤-本底对比度;2周期化疗后随访68Ga-FAPI PET/CT显示肿瘤缩小且髓系肉瘤病灶活性降低。
要点
- 68Ga-FAPI PET/CT在左乳腺髓系肉瘤肿块中的肿瘤-本底对比度远优于18F-FDG PET/CT。
- 2周期化疗后随访68Ga-FAPI PET/CT显示肿瘤缩小且病灶活性降低。
- 髓系肉瘤是急性髓系白血病在髓外部位表现为实性肿瘤的罕见表现。
核心结论
- 在左乳腺髓系肉瘤患者中,68Ga-FAPI PET/CT显示远优于18F-FDG PET/CT的肿瘤-本底对比度,且2周期化疗后随访显示肿瘤缩小及病灶活性降低。
研究设计与样本
- 病例报告,一名18岁女性,左乳腺活检证实髓系肉瘤,接受18F-FDG和68Ga-FAPI PET/CT检查及2周期化疗后随访68Ga-FAPI PET/CT。
主要发现
- 68Ga-FAPI PET/CT在左乳腺肿块中显示的肿瘤-本底对比度远优于18F-FDG PET/CT。
- 2周期化疗后随访68Ga-FAPI PET/CT显示髓系肉瘤病灶肿瘤缩小且活性降低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myeloid sarcoma is a rare presentation of acute myeloid leukemia as a solid tumor at various extramedullary sites. In this case, we report 18F-FDG and 68Ga-FAPI PET/CT findings in an 18-year-old woman with biopsy-proven myeloid sarcoma involving the left breast. 68Ga-FAPI PET/CT showed a far better tumor-to-background contrast than 18F-FDG PET/CT in the left breast mass. Moreover, follow-up 68Ga-FAPI PET/CT after 2 cycles of chemotherapy revealed a reduction in tumor size with decreasing activity in the myeloid sarcoma lesions.
来源:Clin Nucl Med,查看原文。版权归原作者所有。
引用
- Wu S, Lin Z, Shang Q, et al. Use of 68Ga-FAPI PET/CT for Detecting Myeloid Sarcoma of the Breast and Assessing Early Response to Chemotherapy. Clin Nucl Med. 2022. PMID: 35025784. doi:10.1097/RLU.0000000000004028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。